Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde(City Of Hope National Medical Center), Laurie H. Sehn(Spinal Cord Injury BC), Matthew J. Matasar(Memorial Sloan Kettering Cancer Center), Stephen J. Schuster(University of Pennsylvania), Sarit Assouline(Jewish General Hospital), Pratyush Giri(Royal Adelaide Hospital), John Kuruvilla(Princess Margaret Cancer Centre), Miguel Canales(Hospital Universitario La Paz), Sascha Dietrich(Heidelberg University), Keith Fay(The University of Melbourne), Matthew Ku(St Vincent's Hospital Melbourne), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Chan Y. Cheah(The University of Western Australia), Michael C. Wei, Shen Yin, Chi‐Chung Li, Huang Huang(Roche (Canada)), Antonia Kwan, Elicia Penuel, Nancy L. Bartlett(Washington University in St. Louis)
The Lancet Oncology
July 5, 2022
Cited by 419Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis